27 related articles for article (PubMed ID: 15592721)
1. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays.
Sipes NS; Martin MT; Kothiya P; Reif DM; Judson RS; Richard AM; Houck KA; Dix DJ; Kavlock RJ; Knudsen TB
Chem Res Toxicol; 2013 Jun; 26(6):878-95. PubMed ID: 23611293
[TBL] [Abstract][Full Text] [Related]
2. Cloning and expression of ADAM-related metalloproteases in equine laminitis.
Coyne MJ; Cousin H; Loftus JP; Johnson PJ; Belknap JK; Gradil CM; Black SJ; Alfandari D
Vet Immunol Immunopathol; 2009 Jun; 129(3-4):231-41. PubMed ID: 19131116
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Levitt NC; Eskens FA; O'Byrne KJ; Propper DJ; Denis LJ; Owen SJ; Choi L; Foekens JA; Wilner S; Wood JM; Nakajima M; Talbot DC; Steward WP; Harris AL; Verweij J
Clin Cancer Res; 2001 Jul; 7(7):1912-22. PubMed ID: 11448904
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
5. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
[TBL] [Abstract][Full Text] [Related]
7. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
Chiappori AA; Eckhardt SG; Bukowski R; Sullivan DM; Ikeda M; Yano Y; Yamada-Sawada T; Kambayashi Y; Tanaka K; Javle MM; Mekhail T; O'bryant CL; Creaven PJ
Clin Cancer Res; 2007 Apr; 13(7):2091-9. PubMed ID: 17404091
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
Planting A; van der Gaast A; Schöffski P; Bartkowski M; Verheij C; Noe D; Ferrante K; Verweij J
Cancer Chemother Pharmacol; 2005 Feb; 55(2):136-42. PubMed ID: 15592721
[TBL] [Abstract][Full Text] [Related]
9. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.
Rundhaug JE
Clin Cancer Res; 2003 Feb; 9(2):551-4. PubMed ID: 12576417
[No Abstract] [Full Text] [Related]
12. [Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment].
Shimizu T; Saijo N
Nihon Rinsho; 2003 Jun; 61(6):937-42. PubMed ID: 12806939
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]